Analysts Stocks

      Selected Stock Price Target News of the Day — June 23, 2026

      By Mathew Auto

      Three companies drew fresh price target action today. One is in biotech. Another works in chip design software. The third makes optical materials. Definium Therapeutics picked up four analyst price target raises. The move followed the company’s $500 million stock offering. Synopsys got an upgrade from Piper Sandler. It moved from Neutral to Overweight. That call came with a $100 price target increase. Corning kept its Hold rating from Truist. Truist still raised its target by $56, from $149 to $205.

      Definium’s Depression Drug Clears Phase 3, Then Four Analysts Raise Price Targets

      The Trial Data

      Definium Therapeutics is a clinical-stage biotech company. It doesn’t sell any approved drugs yet. But on June 22, it said its Phase 3 EMERGE study hit its main goal. DT120 patients improved 13.3 points on the MADRS depression scale, while patients on placebo improved just 5.2 points over the same six weeks. DT120 is the company’s lead drug. It’s a dissolving tablet for major depressive disorder. Every key secondary goal of the trial also cleared. The company launched a $500 million stock offering the next morning. Four analysts revised their price targets that same day.

      The Four Analyst Moves

      Definium’s EPS came to negative $0.71 per share in the quarter ended March 31. That was on a net loss of $77.1 million. The company held $373.4 million in cash and investments as of that date. The new stock offering added to that total.

      Ami Fadia at Needham raised her target from $38 to $50. She kept her Buy rating. Marc Goodman at Leerink raised his target from $30 to $52. He kept his Outperform rating too. Jay Olson at Oppenheimer set the highest target of the group. He went from $40 to $60 and kept Outperform. Christopher Chen at Baird raised his target too, to $57, per StreetInsider. All four analysts kept their existing ratings. Their four new targets span just $10, from Fadia’s $50 to Olson’s $60.

      Reading The Offering

      All four analysts raised their targets after a dilutive offering. Their updated models show higher fair value per share, even though the new shares are counted in. This pattern is common for one reason. Analysts often believe a capital raise removes execution risk from a drug’s timeline. Definium said the new money would fund clinical work and general costs. A raise this size usually means management expects heavy spending ahead. All four analysts moved the same way. That points to confidence in the drug pipeline, instead of worry about the added shares.

      On AnaChart, Ami Fadia carries a career price target met ratio of 48.98%. That’s across 1,018 documented calls on 41 healthcare and technology stocks. Her average upside on called targets is 39.25%. She reaches it in about 176 days on average. Marc Goodman’s profile shows a 52.14% hit rate across 531 calls on 50 stocks, the highest of the three, though his average upside of 32.38% is the lowest, over the longest wait at about 379 days. Jay Olson at Oppenheimer has a 47.63% met ratio across 988 calls on 65 stocks, though his 44.41% average upside is the highest of the three, reached fastest at about 182 days.

      A Fiscal Q2 Beat Drives Piper Sandler’s Upgrade of Synopsys to Overweight

      Synopsys makes software that chip engineers use to design chips. Engineers also use it to verify and simulate circuits. That category is called electronic design automation, or EDA. Nearly every advanced chip today runs through EDA software at some stage. Apple, Nvidia, and major cloud providers’ chip teams all depend on tools from this space. Synopsys and Cadence Design Systems split most of the EDA market. In 2025, though, Synopsys closed its purchase of Ansys, a simulation software company. Ansys focuses on physics modeling for engineers. That deal pushed Synopsys beyond circuit design. The combined platform now covers far more engineering physics than EDA alone.

      Synopsys posted fiscal second quarter revenue of $2.276 billion. That’s up from $1.604 billion a year earlier. Non-GAAP earnings per share came to $3.35, beating consensus by $0.20. Revenue also beat expectations. Management raised its full-year 2026 guidance on the strength of the quarter. Still, the market took the update in stride.

      The Upgrade

      Clarke Jeffries at Piper Sandler upgraded Synopsys from Neutral to Overweight on June 23. He raised his target from $450 to $550, a $100 jump. Piper Sandler has covered semiconductor and technology names on AnaChart for years. This call is one of the firm’s larger moves on any tech stock lately.

      AI spending on custom silicon has driven demand for EDA tools since 2024. Every custom chip that runs through a foundry like TSMC needs Synopsys software at multiple steps. Hyperscaler chip projects have stayed busy through 2025 and into 2026. That demand supports Synopsys’s licensing revenue and renewal rates. Three things line up behind Jeffries’s upgrade: the Q2 beat, the progress on the Ansys deal, and steady AI chip design work.

      Jeffries held a Neutral rating while the Ansys integration was underway. That integration appears to have gone smoothly. It didn’t disrupt the core EDA business. The Q2 EPS beat of $0.20 likely moved his model most. A steady AI chip spending environment also helped. Those two factors likely explain why the upgrade came now, weeks after the earnings report.

      AI Data Center Demand Pushes Truist’s Corning Price Target Up $56

      Corning makes optical fiber. It’s among the largest producers of it in the world. The company also makes specialty glass for phone and TV screens. It makes lab glassware and auto emissions filters too. Its optical communications unit supplies fiber cable, hardware, and connectivity gear. Telecom carriers and data center operators are its main customers. That unit, though, has driven most of Corning’s growth since the AI buildout picked up in 2024.

      Corning reported first quarter 2026 revenue of $4.35 billion. That’s up 18% from a year earlier. Core EPS grew 30% to $0.70 for the quarter, matching estimates, though optical communications sales grew 36% year over year within that total, well ahead of the company’s overall pace. It was the fastest-growing part of the business.

      Building a large AI data center takes dense networks of optical fiber. That fiber connects server racks, switches, and storage systems. Corning supplies much of it. Two more hyperscale customers signed long-term supply deals in the first quarter. The terms were similar to Corning’s earlier deal with Meta, capped at $6 billion. Management is targeting $20 billion in yearly revenue by the end of 2026.

      The Truist Call

      Matthew Niknam at Truist kept his Hold rating on Corning on June 23, though he raised his target from $149 to $205, a $56 increase. His revised model reflects higher optical communications revenue for 2026 and 2027.

      Corning management has described longer lead times on customer orders lately. Buyers are placing fiber orders further ahead of delivery than in past cycles. That shows customers locking in supply early, based on their own buildout plans. AI data centers need more fiber per server rack than older compute builds did. A modern GPU cluster packs more connections than a traditional server room. Corning’s optical products sit at the center of that design need. Order visibility well into 2026 is the likely reason Niknam raised his revenue assumptions, and his price target, by so much.

      On AnaChart, Matthew Niknam carries a career price target met ratio of 72.37%. That’s across 643 documented calls on 37 stocks. His average upside on called targets is 26.24%, over about 387 days. He worked at Deutsche Bank before joining Truist. His coverage focuses on telecom infrastructure, fiber, and related tech. A 72% hit rate across more than 600 calls stands out for this type of coverage. Still, it sits well ahead of the sub-53% hit rates posted by Definium’s four analysts above. That record gives context for the size of Monday’s move. Niknam’s $56 increase is the largest single-stock target move in Tuesday’s analyst activity on AnaChart.

      AnaChart top daily price target moves table, June 23 2026

      Track records for every analyst above are on anachart.com. Deeper analysis, including retired analysts going back to 2004 and on-demand research, is at analyst price target dataset.